Caprock Group’s Karyopharm Therapeutics KPTI Stock Holding History

Caprock Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-773	Closed	-$7.84K	–	1136
2024 Q4	$7.84K	Buy	+773	New	+$9.35K	﹤0.01%	996

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Caprock Group's KPTI Position: Q1 2025 in Review

Caprock Group sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 773 shares — an estimated $7.84K sold.

Caprock Group first reported a position in KPTI in Q4 2024 and held it in 1 quarter. The position peaked at $7.84K in Q4 2024. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

Caprock Group reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
Caprock Group sold 773 Karyopharm Therapeutics shares in Q1 2025, an estimated $7.84K.
Caprock Group first reported a position in Karyopharm Therapeutics in Q4 2024 and held it in 1 quarter.
Caprock Group's Karyopharm Therapeutics position peaked at $7.84K in Q4 2024.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Caprock Group's 13F filing for Q1 2025, filed 15 May 2025.